Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia

Biochem Cell Biol. 2023 Aug 11. doi: 10.1139/bcb-2022-0374. Online ahead of print.ABSTRACTModulating the immune system to treat diseases, including myeloid malignancies, has resulted in the development of a multitude of novel therapeutics in recent years. Myelodysplastic syndromes or neoplasms (MDS) and acute myeloid leukemia (AML) are hematologic malignancies that arise from defects in hematopoietic stem and progenitor cells (HSPCs). Dysregulated immune responses, especially in innate immune and inflammatory pathways, are highly associated with the acquisition of HSPC defects in MDS and AML pathogenesis. In addition to utilizing the immune system in immunotherapeutic interventions such as CAR-T cell therapy, vaccines, and immune checkpoint inhibitors, mitigating dysregulation of innate immune and inflammatory responses in MDS and AML remains a priority in slowing the initiation and progression of these myeloid malignancies. This review provides a comprehensive summary of the current progress of diverse strategies to modulate the immune system in the treatment of MDS and AML.PMID:37566901 | DOI:10.1139/bcb-2022-0374
Source: Biochemistry and Cell Biology - Category: Biochemistry Authors: Source Type: research